Hodgkin Lymphoma Archives - Page 3 of 9

A new study reveals that an aging world population is the predominant contributor to a 126% increase

Current Treatment Options for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

By

November 24, 2020

Investigators summarize current literature surrounding the treatment of NLPHL and discuss treatment considerations for 2 clinical cases.

Over half of evaluable patients who received an infusion of tisagenlecleucel achieved response.

Lymphoma

Causes of Mortality in Adults Treated for Hodgkin Lymphoma

By

Susan Moench, PhD, PA-C

November 6, 2020

Adults treated for Hodgkin lymphoma have an increased risk of death from heart disease, interstitial lung disease, infections, and adverse effects of therapy.

Lymphoma

What Does Radiation Do to Organs at Risk in Patients With Lymphoma?

By

Steve Fiorillo

November 6, 2020

Depending on the type and stage of lymphoma, physicians may choose to avoid having their patients undergo radiation therapy for fear of potential toxic effects in organs.

Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve

Lymphoma

Conventional Chemotherapy May Be Effective in Early-Stage Hodgkin Lymphoma After Relapse

By

Jonathan Goodman, MPhil

October 27, 2020

Among patients with early-stage, favorable Hodgkin lymphoma, treatment regimens with conventional chemotherapy may be effective in a subset of patients.

Lymphoma

Promising, Early Results for Combined HDAC and mTOR Inhibition in Relapsed/Refractory Hodgkin Lymphoma

By

Susan Moench, PhD, PA-C

October 21, 2020

Responses were also observed in patients previously treated with HDAC or mTOR inhibitors.

Lymphoma

Modern Radiation Therapy Limits Radiation Doses to Organs at Risk in Hodgkin Lymphoma

By

Lauren Dembeck, PhD

October 20, 2020

Combined modality therapy for early-stage favorable HL yielded excellent outcomes and limited excess radiation doses to organs at risk.

Lymphoma

Keytruda Approval Expands Classical Hodgkin Lymphoma Indication

By

Brian Park, PharmD

October 20, 2020

The expanded approval was based on data from the randomized, open-label, phase 3 KEYNOTE-204 trial.

Lymphoma

Brentuximab Vedotin Plus Nivolumab as Chemotherapy-Free Strategy for Hodgkin Lymphoma in Older Patients

By

Lauren Dembeck, PhD

October 19, 2020

Findings suggest that brentuximab vedotin plus nivolumab was well tolerated and active in older patients with previously untreated HL with comorbidities.

Lymphoma

Maternal, Fetal Considerations for the Treatment and Management of Lymphoma During Pregnancy

By

Jessica Nye, PhD

October 13, 2020

Although 1 in 1000 lymphoma diagnoses occurs in pregnancy, literature on best practices for treatment in this patient group is limited.

Patients with anemia had worse in-hospital outcomes.

Lymphoma

Classical Hodgkin Lymphoma: Patients Face Unnecessary Risk of Death Unrelated to Lymphoma

By

Jonathan Goodman, MPhil

October 5, 2020

Investigators characterized the risks of stage- and cause-specific mortality among patients with classical Hodgkin lymphoma treated with chemotherapy.